Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight

Expert Rev Clin Pharmacol. 2020 Aug;13(8):807-811. doi: 10.1080/17512433.2020.1798760. Epub 2020 Jul 25.

Authors

Lucas A D Nicolau¹, Isabela R S G Nolêto², Jand V R Medeiros²

Affiliations

¹ Department of Medicine, Federal University of Parnaíba Delta , Parnaíba, Brazil.
² Biotechnology and Biodiversity Center Research (BIOTEC), Federal University of Parnaíba Delta , Parnaíba, Brazil.

No abstract available

Keywords: ACE2; SARS-CoV-2; coronavirus; diminazene; lung injury; pharmacology.

Publication types

Editorial

MeSH terms

Adaptive Immunity / drug effects
Angiotensin-Converting Enzyme 2
Antiviral Agents / pharmacology*
Betacoronavirus* / drug effects
Betacoronavirus* / physiology
COVID-19
Coronavirus Infections* / drug therapy
Coronavirus Infections* / immunology
Coronavirus Infections* / virology
Drug Discovery
Humans
Lung / metabolism
Pandemics*
Peptidyl-Dipeptidase A / metabolism*
Pneumonia, Viral* / drug therapy
Pneumonia, Viral* / immunology
Pneumonia, Viral* / virology
Receptors, Virus / metabolism
SARS-CoV-2
Spike Glycoprotein, Coronavirus / metabolism*
Treatment Outcome
Virus Internalization / drug effects

Substances

Antiviral Agents
Receptors, Virus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2

Grants and funding

The authors gratefully acknowledge the financial support from CNPq (Brazil) and Research Foundation for the State of Piauí—FAPEPI.